Precision radiotherapy for patients with locally advanced non-small cell lung cancer in the era of immunotherapy and precision medicine

A report by Roswit et al. published in 1960 showing that radiotherapy extended the survival of patients, compared with no treatment, is the oldest finding demonstrating the significance of radiotherapy for the treatment of lung cancer (1). In the 1970s, a randomized trial (Radiation Therapy Oncology Group, RTOG 7301) was conducted to select the optimum dose from 40 to 60 Gy (2), and 60 Gy was established as the subsequent standard dose. Since then, thoracic radiotherapy has played an important role in treatment strategies for non-small cell lung cancer (NSCLC).